# Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab

> **NCT07013123** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University Hospital, Montpellier** · enrollment: 38 (estimated)

## Conditions studied

- Severe Asthma
- Allergy to House Dust Mites

## Interventions

- **DRUG:** Tezepelumab
- **DRUG:** Acarizax
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07013123
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2029-08-18
- **Final completion:** 2029-08-18
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07013123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07013123, "Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07013123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*